25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

APVO (Aptevo Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aptevo Therapeutics Inc together

I guess you are interested in Aptevo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Aptevo Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Aptevo Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Aptevo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aptevo Therapeutics Inc

I send you an email if I find something interesting about Aptevo Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aptevo Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aptevo Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$-1.01
Expected worth in 1 year
$-11.06
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-10.05
Return On Investment
-330.6%

For what price can you sell your share?

Current Price per Share
$3.04
Expected price per share
$2.81 - $18.85
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aptevo Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$3.04
Intrinsic Value Per Share
$-213.42 - $105.60
Total Value Per Share
$-214.43 - $104.59

2.2. Growth of Aptevo Therapeutics Inc (5 min.)




Is Aptevo Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.4m$12.3m-$9.2m-305.2%

How much money is Aptevo Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.9m-$6.7m$828.7k14.0%
Net Profit Margin0.0%-163.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Aptevo Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#778 / 881

Most Revenue
#764 / 881

Most Profit
#445 / 881

Most Efficient
#268 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aptevo Therapeutics Inc?

Welcome investor! Aptevo Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aptevo Therapeutics Inc.

First you should know what it really means to hold a share of Aptevo Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Aptevo Therapeutics Inc is $3.04. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aptevo Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aptevo Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.01. Based on the TTM, the Book Value Change Per Share is $-2.51 per quarter. Based on the YOY, the Book Value Change Per Share is $-6.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aptevo Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-4.39-144.5%-6.25-205.5%-10.01-329.2%-4.46-146.7%-6.88-226.4%-14.45-475.4%
Usd Book Value Change Per Share-4.27-140.5%-2.51-82.7%-6.35-209.0%0.6421.1%-1.17-38.6%-3.53-116.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.1%0.7324.2%0.3712.1%
Usd Total Gains Per Share-4.27-140.5%-2.51-82.7%-6.35-208.9%0.6421.2%-0.44-14.4%-3.16-104.0%
Usd Price Per Share1.16-1.49-1.67-1.97-7.92-4.88-
Price to Earnings Ratio-0.07--0.08--0.04--0.06--0.19--0.09-
Price-to-Total Gains Ratio-0.27--1.13--0.21--0.38--0.21--0.14-
Price to Book Ratio-1.15-0.06-0.15-0.10-0.69-0.36-
Price-to-Total Gains Ratio-0.27--1.13--0.21--0.38--0.21--0.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.04
Number of shares328
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.73
Usd Book Value Change Per Share-2.51-1.17
Usd Total Gains Per Share-2.51-0.44
Gains per Quarter (328 shares)-824.22-143.88
Gains per Year (328 shares)-3,296.88-575.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3297-3307963-1539-586
20-6594-66041927-3078-1162
30-9891-99012890-4616-1738
40-13188-131983853-6155-2314
50-16484-164954816-7694-2890
60-19781-197925780-9233-3466
70-23078-230896743-10772-4042
80-26375-263867706-12310-4618
90-29672-296838670-13849-5194
100-32969-329809633-15388-5770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%4.036.00.010.0%4.038.00.09.5%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%5.015.00.025.0%10.028.02.025.0%11.028.03.026.2%
Dividend per Share0.00.04.00.0%2.00.010.016.7%3.00.017.015.0%3.00.037.07.5%3.00.039.07.1%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%11.027.02.027.5%12.027.03.028.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aptevo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---4.270-2.513-41%-6.353+49%0.642-765%-1.173-73%-3.529-17%
Book Value Per Share---1.0103.853-126%18.257-106%17.251-106%14.385-107%51.796-102%
Current Ratio--0.6691.464-54%2.732-76%2.708-75%2.536-74%2.888-77%
Debt To Asset Ratio--1.1770.820+43%0.514+129%0.588+100%0.693+70%0.543+117%
Debt To Equity Ratio---1.762-100%1.136-100%1.224-100%4.854-100%2.844-100%
Dividend Per Share----0%0.003-100%0.002-100%0.734-100%0.367-100%
Enterprise Value---5984188.720-1714346.098-71%5637293.750-206%5250409.634-214%5775033.281-204%7994293.160-175%
Eps---4.394-6.249+42%-10.007+128%-4.459+1%-6.883+57%-14.453+229%
Ev To Ebitda Ratio--0.2310.074+211%-0.201+187%-0.174+175%-0.204+189%-0.195+184%
Free Cash Flow Per Share---4.508-6.327+40%-8.499+89%-6.349+41%-7.197+60%-11.846+163%
Free Cash Flow To Equity Per Share---4.508-1.887-58%-5.585+24%-3.842-15%1.116-504%-2.762-39%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.024-2%
Intrinsic Value_10Y_max--105.600----------
Intrinsic Value_10Y_min---213.417----------
Intrinsic Value_1Y_max---20.215----------
Intrinsic Value_1Y_min---43.245----------
Intrinsic Value_3Y_max---37.267----------
Intrinsic Value_3Y_min---111.771----------
Intrinsic Value_5Y_max---26.023----------
Intrinsic Value_5Y_min---159.866----------
Market Cap2052000.000+18%1691811.2802076403.903-19%1124043.750+51%1684159.634+0%5557633.281-70%3403181.515-50%
Net Profit Margin----0%-1.6360%-1.3580%-2.5500%-2.0990%
Operating Margin----0%-1.7690%-0.3840%-1.7630%-1.8710%
Operating Ratio----0%1.769-100%0.380-100%3.210-100%3.055-100%
Pb Ratio-3.010-162%-1.1490.062-1959%0.151-860%0.103-1218%0.694-265%0.363-417%
Pe Ratio-0.173-162%-0.066-0.082+25%-0.040-39%-0.055-16%-0.192+191%-0.094+42%
Price Per Share3.040+62%1.1601.489-22%1.665-30%1.966-41%7.916-85%4.883-76%
Price To Free Cash Flow Ratio-0.169-162%-0.064-0.088+37%-0.046-28%-0.066+3%-0.233+262%-0.256+298%
Price To Total Gains Ratio-0.712-162%-0.272-1.133+317%-0.213-22%-0.384+42%-0.210-23%-0.138-49%
Quick Ratio--0.3971.152-66%2.451-84%2.393-83%2.256-82%2.941-87%
Return On Assets---0.768-0.476-38%-0.283-63%-0.112-85%-0.134-83%-0.134-83%
Return On Equity----0.9500%-0.6310%-0.2840%-0.7540%-0.5050%
Total Gains Per Share---4.270-2.513-41%-6.350+49%0.644-763%-0.439-90%-3.162-26%
Usd Book Value---1473000.0003041250.000-148%12323750.000-112%11791583.333-112%9797700.000-115%35006650.000-104%
Usd Book Value Change Per Share---4.270-2.513-41%-6.353+49%0.642-765%-1.173-73%-3.529-17%
Usd Book Value Per Share---1.0103.853-126%18.257-106%17.251-106%14.385-107%51.796-102%
Usd Dividend Per Share----0%0.003-100%0.002-100%0.734-100%0.367-100%
Usd Enterprise Value---5984188.720-1714346.098-71%5637293.750-206%5250409.634-214%5775033.281-204%7994293.160-175%
Usd Eps---4.394-6.249+42%-10.007+128%-4.459+1%-6.883+57%-14.453+229%
Usd Free Cash Flow---6575000.000-5927250.000-10%-5736750.000-13%-4837416.667-26%-5189450.000-21%-8161850.000+24%
Usd Free Cash Flow Per Share---4.508-6.327+40%-8.499+89%-6.349+41%-7.197+60%-11.846+163%
Usd Free Cash Flow To Equity Per Share---4.508-1.887-58%-5.585+24%-3.842-15%1.116-504%-2.762-39%
Usd Market Cap2052000.000+18%1691811.2802076403.903-19%1124043.750+51%1684159.634+0%5557633.281-70%3403181.515-50%
Usd Price Per Share3.040+62%1.1601.489-22%1.665-30%1.966-41%7.916-85%4.883-76%
Usd Profit---6408000.000-5926000.000-8%-6754750.000+5%948333.333-776%-2384250.000-63%-7289975.000+14%
Usd Revenue----0%225500.000-100%-184333.3330%875150.000-100%4189000.000-100%
Usd Total Gains Per Share---4.270-2.513-41%-6.350+49%0.644-763%-0.439-90%-3.162-26%
 EOD+6 -2MRQTTM+9 -22YOY+20 -153Y+13 -215Y+9 -2610Y+11 -25

3.3 Fundamental Score

Let's check the fundamental score of Aptevo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.173
Price to Book Ratio (EOD)Between0-1-3.010
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.397
Current Ratio (MRQ)Greater than10.669
Debt to Asset Ratio (MRQ)Less than11.177
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.768
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Aptevo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.934
Ma 20Greater thanMa 503.851
Ma 50Greater thanMa 1006.209
Ma 100Greater thanMa 20025.905
OpenGreater thanClose3.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2025-06-18 23:33:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Aptevo Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Aptevo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-163.6%+163.6%
TTM-5Y-255.0%+255.0%
5Y-255.0%10Y-209.9%-45.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM--139.0%+139.0%
YOY-163.6%-194.4%+30.8%
3Y-135.8%-248.5%+112.7%
5Y-255.0%-343.3%+88.3%
10Y-209.9%-488.9%+279.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Aptevo Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Aptevo Therapeutics Inc to theΒ Biotechnology industry mean.
  • -76.8% Return on Assets means thatΒ Aptevo Therapeutics Inc generatedΒ $-0.77 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aptevo Therapeutics Inc:

  • The MRQ is -76.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -47.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-76.8%TTM-47.6%-29.2%
TTM-47.6%YOY-28.3%-19.3%
TTM-47.6%5Y-13.4%-34.2%
5Y-13.4%10Y-13.4%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-76.8%-11.6%-65.2%
TTM-47.6%-11.7%-35.9%
YOY-28.3%-11.4%-16.9%
3Y-11.2%-11.9%+0.7%
5Y-13.4%-12.1%-1.3%
10Y-13.4%-13.8%+0.4%
4.3.1.3. Return on Equity

Shows how efficient Aptevo Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Aptevo Therapeutics Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Aptevo Therapeutics Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-95.0%+95.0%
TTM-95.0%YOY-63.1%-31.9%
TTM-95.0%5Y-75.4%-19.5%
5Y-75.4%10Y-50.5%-25.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.5%+13.5%
TTM-95.0%-15.0%-80.0%
YOY-63.1%-14.5%-48.6%
3Y-28.4%-16.9%-11.5%
5Y-75.4%-17.9%-57.5%
10Y-50.5%-19.9%-30.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aptevo Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Aptevo Therapeutics Inc is operatingΒ .

  • Measures how much profit Aptevo Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Aptevo Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-176.9%+176.9%
TTM-5Y-176.3%+176.3%
5Y-176.3%10Y-187.1%+10.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--249.7%+249.7%
YOY-176.9%-208.4%+31.5%
3Y-38.4%-221.7%+183.3%
5Y-176.3%-344.1%+167.8%
10Y-187.1%-470.4%+283.3%
4.3.2.2. Operating Ratio

Measures how efficient Aptevo Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.769-1.769
TTM-5Y3.210-3.210
5Y3.21010Y3.055+0.155
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM-2.680-2.680
YOY1.7693.080-1.311
3Y0.3803.621-3.241
5Y3.2104.734-1.524
10Y3.0556.546-3.491
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aptevo Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aptevo Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.67Β means the company has $0.67 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.669. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.464. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.669TTM1.464-0.795
TTM1.464YOY2.732-1.268
TTM1.4645Y2.536-1.072
5Y2.53610Y2.888-0.352
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6693.659-2.990
TTM1.4643.834-2.370
YOY2.7324.141-1.409
3Y2.7084.661-1.953
5Y2.5365.756-3.220
10Y2.8886.151-3.263
4.4.3.2. Quick Ratio

Measures if Aptevo Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Aptevo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.40Β means the company can pay off $0.40 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.397. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.152. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.397TTM1.152-0.755
TTM1.152YOY2.451-1.299
TTM1.1525Y2.256-1.104
5Y2.25610Y2.941-0.685
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3972.799-2.402
TTM1.1523.143-1.991
YOY2.4513.794-1.343
3Y2.3934.307-1.914
5Y2.2565.707-3.451
10Y2.9416.457-3.516
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aptevo Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Aptevo Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Aptevo Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.18Β means that Aptevo Therapeutics Inc assets areΒ financed with 117.7% credit (debt) and the remaining percentage (100% - 117.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 1.177. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.820. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.177TTM0.820+0.356
TTM0.820YOY0.514+0.306
TTM0.8205Y0.693+0.127
5Y0.69310Y0.543+0.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1770.324+0.853
TTM0.8200.347+0.473
YOY0.5140.329+0.185
3Y0.5880.340+0.248
5Y0.6930.349+0.344
10Y0.5430.379+0.164
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Aptevo Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Aptevo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.762-1.762
TTM1.762YOY1.136+0.626
TTM1.7625Y4.854-3.091
5Y4.85410Y2.844+2.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM1.7620.435+1.327
YOY1.1360.412+0.724
3Y1.2240.446+0.778
5Y4.8540.460+4.394
10Y2.8440.509+2.335
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Aptevo Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Aptevo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.07 means the investor is paying $-0.07Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is -0.173. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.066. Based on the earnings, the company is expensive. -2
  • The TTM is -0.082. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.173MRQ-0.066-0.107
MRQ-0.066TTM-0.082+0.016
TTM-0.082YOY-0.040-0.042
TTM-0.0825Y-0.192+0.109
5Y-0.19210Y-0.094-0.098
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.173-2.282+2.109
MRQ-0.066-2.062+1.996
TTM-0.082-2.541+2.459
YOY-0.040-3.722+3.682
3Y-0.055-3.754+3.699
5Y-0.192-6.100+5.908
10Y-0.094-6.653+6.559
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is -0.169. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.064. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.088. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.169MRQ-0.064-0.104
MRQ-0.064TTM-0.088+0.024
TTM-0.088YOY-0.046-0.042
TTM-0.0885Y-0.233+0.145
5Y-0.23310Y-0.256+0.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.169-3.101+2.932
MRQ-0.064-2.689+2.625
TTM-0.088-3.594+3.506
YOY-0.046-4.363+4.317
3Y-0.066-5.065+4.999
5Y-0.233-8.478+8.245
10Y-0.256-9.273+9.017
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Aptevo Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -1.15 means the investor is paying $-1.15Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is -3.010. Based on the equity, the company is expensive. -2
  • The MRQ is -1.149. Based on the equity, the company is expensive. -2
  • The TTM is 0.062. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-3.010MRQ-1.149-1.861
MRQ-1.149TTM0.062-1.210
TTM0.062YOY0.151-0.089
TTM0.0625Y0.694-0.632
5Y0.69410Y0.363+0.332
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.0101.932-4.942
MRQ-1.1491.848-2.997
TTM0.0622.119-2.057
YOY0.1512.469-2.318
3Y0.1032.526-2.423
5Y0.6943.667-2.973
10Y0.3634.351-3.988
4.6.2. Total Gains per Share

2.4. Latest News of Aptevo Therapeutics Inc

Does Aptevo Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Aptevo Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-01
23:19
Aptevo regains Nasdaq compliance following $15.9 million equity raiseRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aptevo Therapeutics Inc.

4.8.1. Institutions holding Aptevo Therapeutics Inc

Institutions are holding 3.306% of the shares of Aptevo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Geode Capital Management, LLC0.078010526105260
2025-03-31Tower Research Capital LLC0.02410.000132552169199.7238
2025-03-31Bank of America Corp0.017202318231457850
2024-12-31UBS Group AG0.005807837830
2025-03-31SBI Securities Co Ltd0.00520701570435.1145
2025-03-31BlackRock Inc0.000202400
2025-03-31Morgan Stanley - Brokerage Accounts004-3923-99.8981
2025-03-31Advisor Group Holdings, Inc.00110
2024-12-31Jane Street Group LLC000-465-100
2024-12-31Wells Fargo & Co000-1-100
2024-12-31Northern Trust Investments N A000-5-100
2024-12-31Hudson Bay Capital Management LP000-25279-100
2024-12-31Citadel Advisors Llc000-3016-100
2025-03-31Center For Financial Planning Inc000-5-100
2025-03-31Diadema Partners LP000-4050-100
2024-12-31Renaissance Technologies Corp000-988-100
2025-03-31JPMorgan Chase & Co000-4529-100
2024-12-31PNC Financial Services Group Inc00000
2024-12-31Two Sigma Investments LLC000-384-100
2025-03-31Virtu Financial LLC000-21627-100
Total 0.13050.000117612-47909-272.0%

4.9.2. Funds holding Aptevo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Fidelity Extended Market Index0.06220839800
2025-04-30Fidelity Series Total Market Index0.0158021281460218.5629
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.000405600
2024-12-31CIMA Global Value SICAV0.00010.00028-1-11.1111
2025-04-30Franklin U.S. Small Cap Equity I00600
2025-03-31NT Ext Equity Mkt Idx Fd - NL00200
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T200200
2025-03-31NT Quality Small Cap Core00200
2025-03-31NT Quality SCC US Fund - L00200
2024-09-30BNYM Mellon NSL Mkt Completion Fund Inst00220
2025-03-31BNYM Mellon SL Market Completion UC100100
Total 0.07850.000210607+1461+13.8%

5.3. Insider Transactions

Insiders are holding 3.111% of the shares of Aptevo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-11-22Kevin C TangSELL5802309.32
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Stockholder Equity 6,103-1,6404,463-434,4203354,755-6,228-1,473
Net Debt  -5,0361,995-3,041118-2,923-1,162-4,0856,3682,283
Net Working Capital  5,776-1,6164,160-304,1303224,452-6,238-1,786
Net Invested Capital  6,103-1,6404,463-434,4203354,755-6,228-1,473



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets8,342
Total Liabilities9,815
Total Stockholder Equity-1,473
 As reported
Total Liabilities 9,815
Total Stockholder Equity+ -1,473
Total Assets = 8,342

Assets

Total Assets8,342
Total Current Assets3,607
Long-term Assets4,735
Total Current Assets
Cash And Cash Equivalents 2,139
Other Current Assets 1,468
Total Current Assets  (as reported)3,607
Total Current Assets  (calculated)3,607
+/-0
Long-term Assets
Property Plant Equipment 4,735
Long-term Assets  (as reported)4,735
Long-term Assets  (calculated)4,735
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,393
Long-term Liabilities4,422
Total Stockholder Equity-1,473
Total Current Liabilities
Other Current Liabilities 5,393
Total Current Liabilities  (as reported)5,393
Total Current Liabilities  (calculated)5,393
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,422
Long-term Liabilities  (as reported)4,422
Long-term Liabilities  (calculated)4,422
+/-0
Total Stockholder Equity
Common Stock84
Retained Earnings -253,985
Other Stockholders Equity 252,428
Total Stockholder Equity (as reported)-1,473
Total Stockholder Equity (calculated)-1,473
+/-0
Other
Capital Stock84
Cash and Short Term Investments 2,139
Common Stock Shares Outstanding 1,458
Liabilities and Stockholders Equity 8,342
Net Debt 2,283
Net Invested Capital -1,473
Net Working Capital -1,786
Property Plant and Equipment Gross 4,735
Short Long Term Debt Total 4,422



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
119,971
0
0
0
112,456
141,589
118,159
100,623
91,858
97,793
86,891
131,022
117,007
100,212
89,997
78,934
67,494
80,841
66,127
60,556
53,408
25,244
18,509
37,420
53,547
68,753
71,474
64,005
56,601
45,184
38,799
31,695
34,215
34,969
28,912
27,129
24,842
17,629
14,921
15,146
15,591
8,342
8,34215,59115,14614,92117,62924,84227,12928,91234,96934,21531,69538,79945,18456,60164,00571,47468,75353,54737,42018,50925,24453,40860,55666,12780,84167,49478,93489,997100,212117,007131,02286,89197,79391,858100,623118,159141,589112,456000119,971
   > Total Current Assets 
41,551
3,593
0
0
35,134
64,407
39,847
79,429
71,414
77,396
67,193
115,322
95,084
77,160
66,247
60,395
48,689
57,642
43,672
36,789
29,995
14,825
10,488
30,653
47,264
62,850
65,765
58,873
52,570
41,672
31,400
24,618
27,450
28,485
22,680
21,126
19,066
12,074
9,579
10,012
10,659
3,607
3,60710,65910,0129,57912,07419,06621,12622,68028,48527,45024,61831,40041,67252,57058,87365,76562,85047,26430,65310,48814,82529,99536,78943,67257,64248,68960,39566,24777,16095,084115,32267,19377,39671,41479,42939,84764,40735,134003,59341,551
       Cash And Cash Equivalents 
3,593
-3,593
0
0
4,637
45,000
5,496
10,894
9,676
14,014
22,269
75,830
7,095
11,830
7,228
28,447
30,635
37,011
20,957
17,683
12,448
12,258
7,599
24,942
39,979
57,524
60,394
52,118
45,044
34,991
29,431
22,150
22,635
25,328
21,006
19,110
16,904
10,250
8,066
7,753
8,714
2,139
2,1398,7147,7538,06610,25016,90419,11021,00625,32822,63522,15029,43134,99145,04452,11860,39457,52439,97924,9427,59912,25812,44817,68320,95737,01130,63528,4477,22811,8307,09575,83022,26914,0149,67610,8945,49645,0004,63700-3,5933,593
       Short-term Investments 
0
7,186
0
0
0
0
400
49,785
44,849
46,877
25,958
20,946
73,688
49,824
37,503
9,192
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000009,19237,50349,82473,68820,94625,95846,87744,84949,78540000007,1860
       Net Receivables 
15,130
0
0
0
7,832
4,845
8,514
2,958
4,284
1,926
4,715
528
2,141
3,098
6,145
6,202
5,220
5,801
7,378
7,918
7,022
7,022
288
1,463
2,369
2,421
3,110
3,096
3,664
3,114
0
0
2,500
0
0
0
0
0
0
0
0
0
0000000002,500003,1143,6643,0963,1102,4212,3691,4632887,0227,0227,9187,3785,8015,2206,2026,1453,0982,1415284,7151,9264,2842,9588,5144,8457,83200015,130
       Inventory 
17,625
0
0
0
20,322
9,127
20,130
11,574
6,639
8,063
7,984
1,237
1,028
1,285
2,970
3,969
1,785
4,346
6,967
7,482
6,139
6,139
2,503
4,042
4,783
2,822
2,195
3,650
3,082
2,690
0
0
1,571
0
0
0
0
0
0
0
0
0
0000000001,571002,6903,0823,6502,1952,8224,7834,0422,5036,1396,1397,4826,9674,3461,7853,9692,9701,2851,0281,2377,9848,0636,63911,57420,1309,12720,32200017,625
       Other Current Assets 
5,203
0
0
0
2,343
47,363
5,707
4,218
5,966
6,516
6,267
16,781
11,132
11,123
12,401
12,585
11,049
10,484
8,370
3,706
4,386
2,567
2,601
4,248
4,916
2,905
2,261
3,659
3,862
3,567
1,969
2,468
2,315
3,157
1,674
2,016
2,162
1,824
1,513
2,259
1,945
1,468
1,4681,9452,2591,5131,8242,1622,0161,6743,1572,3152,4681,9693,5673,8623,6592,2612,9054,9164,2482,6012,5674,3863,7068,37010,48411,04912,58512,40111,12311,13216,7816,2676,5165,9664,2185,70747,3632,3430005,203
   > Long-term Assets 
0
-3,593
0
0
77,322
77,182
78,312
21,194
20,444
20,397
19,698
15,700
21,923
23,052
23,750
18,539
18,805
23,199
22,455
23,767
23,413
10,419
8,021
6,767
6,283
5,903
5,709
5,132
4,031
3,512
7,399
7,077
6,765
6,484
6,232
6,003
5,776
5,555
5,342
5,134
4,932
4,735
4,7354,9325,1345,3425,5555,7766,0036,2326,4846,7657,0777,3993,5124,0315,1325,7095,9036,2836,7678,02110,41923,41323,76722,45523,19918,80518,53923,75023,05221,92315,70019,69820,39720,44421,19478,31277,18277,32200-3,5930
       Property Plant Equipment 
3,202
0
0
0
4,179
4,624
6,342
6,139
5,910
6,384
6,205
6,163
5,843
5,936
5,638
5,608
5,202
9,459
8,874
8,252
7,693
7,133
6,571
6,010
5,537
5,157
4,963
4,386
3,963
3,444
7,399
7,077
6,765
6,484
6,232
6,003
5,776
5,555
5,342
5,134
4,932
4,735
4,7354,9325,1345,3425,5555,7766,0036,2326,4846,7657,0777,3993,4443,9634,3864,9635,1575,5376,0106,5717,1337,6938,2528,8749,4595,2025,6085,6385,9365,8436,1636,2056,3845,9106,1396,3424,6244,1790003,202
       Goodwill 
13,902
0
0
0
13,902
13,902
13,902
0
0
0
0
0
0
0
0
0
0
0
0
0
-830
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000-830000000000000013,90213,90213,90200013,902
       Intangible Assets 
75,218
0
0
0
59,241
58,656
58,068
15,055
14,534
14,013
13,493
6,287
6,080
5,873
5,665
5,458
5,250
5,043
4,835
4,628
5,250
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000005,2504,6284,8355,0435,2505,4585,6655,8736,0806,28713,49314,01314,53415,05558,06858,65659,24100075,218
       Long-term Assets Other 
0
-3,593
0
0
0
0
-506
15,055
14,534
0
0
3,250
10,000
11,243
12,447
7,473
8,353
8,697
8,746
10,887
11,300
3,286
1,450
757
746
746
746
746
68
68
-7,399
-7,077
-6,765
-6,484
-6,232
0
0
0
0
0
0
0
0000000-6,232-6,484-6,765-7,077-7,39968687467467467467571,4503,28611,30010,8878,7468,6978,3537,47312,44711,24310,0003,2500014,53415,055-5060000-3,5930
> Total Liabilities 
25,363
0
0
0
23,838
22,743
20,962
36,873
41,292
36,307
35,471
40,712
34,972
31,848
33,967
34,934
37,088
41,711
39,928
40,811
41,566
10,092
9,859
35,218
36,953
58,249
57,593
56,713
55,385
51,068
15,752
15,933
16,241
11,713
12,659
12,411
12,621
11,526
10,458
10,726
10,836
9,815
9,81510,83610,72610,45811,52612,62112,41112,65911,71316,24115,93315,75251,06855,38556,71357,59358,24936,95335,2189,85910,09241,56640,81139,92841,71137,08834,93433,96731,84834,97240,71235,47136,30741,29236,87320,96222,74323,83800025,363
   > Total Current Liabilities 
19,835
0
0
0
19,943
18,690
17,028
15,233
19,544
14,459
11,883
14,870
18,510
17,273
18,102
15,442
17,610
18,290
16,598
37,252
38,239
6,993
7,002
7,417
14,539
29,344
30,864
32,380
34,757
23,857
7,003
7,786
8,706
5,797
6,911
6,836
7,224
6,298
5,419
5,882
6,207
5,393
5,3936,2075,8825,4196,2987,2246,8366,9115,7978,7067,7867,00323,85734,75732,38030,86429,34414,5397,4177,0026,99338,23937,25216,59818,29017,61015,44218,10217,27318,51014,87011,88314,45919,54415,23317,02818,69019,94300019,835
       Short-term Debt 
0
0
0
0
5,572
4,142
5,251
-8,951
18,383
18,435
18,745
17,484
3,333
5,333
4,167
0
0
1,081
0
19,707
19,863
19,863
0
0
5,000
10,167
10,667
11,167
11,667
2,000
2,000
2,000
2,000
0
0
0
0
0
0
0
0
0
0000000002,0002,0002,0002,00011,66711,16710,66710,1675,0000019,86319,86319,70701,081004,1675,3333,33317,48418,74518,43518,383-8,9515,2514,1425,5720000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
18,383
18,435
18,745
17,484
3,333
5,333
4,167
0
0
1,081
0
19,707
19,863
0
0
0
5,000
10,167
10,667
11,167
11,667
2,000
2,000
2,000
2,000
0
0
0
0
0
0
0
0
0
0000000002,0002,0002,0002,00011,66711,16710,66710,1675,00000019,86319,70701,081004,1675,3333,33317,48418,74518,43518,38300000000
       Accounts payable 
11,472
0
0
0
10,084
12,197
11,192
8,951
15,498
11,271
8,293
11,327
7,350
7,263
9,535
9,808
11,671
11,043
11,904
12,073
6,428
4,701
4,662
3,911
5,583
5,352
5,196
3,687
3,462
3,910
3,269
3,243
3,499
4,134
4,873
4,000
3,984
3,720
3,736
3,532
0
0
003,5323,7363,7203,9844,0004,8734,1343,4993,2433,2693,9103,4623,6875,1965,3525,5833,9114,6624,7016,42812,07311,90411,04311,6719,8089,5357,2637,35011,3278,29311,27115,4988,95111,19212,19710,08400011,472
       Other Current Liabilities 
8,363
0
0
0
9,859
6,493
5,442
5,642
18,733
13,581
10,439
14,870
7,827
4,677
4,400
5,634
5,939
7,247
4,694
5,472
11,948
2,292
2,340
3,506
3,956
13,825
15,001
17,526
19,628
17,947
1,734
2,543
3,207
1,663
2,038
2,836
3,240
2,578
1,683
2,350
6,207
5,393
5,3936,2072,3501,6832,5783,2402,8362,0381,6633,2072,5431,73417,94719,62817,52615,00113,8253,9563,5062,3402,29211,9485,4724,6947,2475,9395,6344,4004,6777,82714,87010,43913,58118,7335,6425,4426,4939,8590008,363
   > Long-term Liabilities 
0
0
0
0
3,895
4,053
3,934
21,640
21,748
21,848
23,588
25,842
16,462
14,575
15,865
19,492
19,478
23,421
23,330
3,559
3,327
3,099
2,857
27,801
22,414
28,905
26,729
24,333
20,628
27,211
8,749
8,147
7,535
5,916
5,748
5,575
5,397
5,228
5,039
4,844
4,629
4,422
4,4224,6294,8445,0395,2285,3975,5755,7485,9167,5358,1478,74927,21120,62824,33326,72928,90522,41427,8012,8573,0993,3273,55923,33023,42119,47819,49215,86514,57516,46225,84223,58821,84821,74821,6403,9344,0533,8950000
       Long term Debt Total 
0
0
0
0
0
0
0
18,111
18,383
18,435
18,745
17,484
15,728
13,975
15,400
19,143
19,278
19,415
19,558
0
0
0
0
25,199
0
4,614
4,323
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000004,3234,614025,199000019,55819,41519,27819,14315,40013,97515,72817,48418,74518,43518,38318,1110000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-5,572
-4,142
-5,251
8,951
-18,383
-18,435
-18,745
-17,484
-3,333
-5,333
-4,167
0
0
2,914
3,759
-16,160
-16,536
-16,764
2,857
2,602
-2,640
-8,048
-8,798
-9,557
-10,326
-935
4,390
4,237
4,079
5,916
5,748
5,575
5,397
5,214
5,025
4,830
4,629
4,422
4,4224,6294,8305,0255,2145,3975,5755,7485,9164,0794,2374,390-935-10,326-9,557-8,798-8,048-2,6402,6022,857-16,764-16,536-16,1603,7592,91400-4,167-5,333-3,333-17,484-18,745-18,435-18,3838,951-5,251-4,142-5,5720000
       Long-term Liabilities Other 
0
0
0
0
0
0
88
433
469
611
2,047
8,358
734
600
465
349
200
4,006
13
12
3,327
3,099
2,857
2,602
0
24,291
20,537
18,711
15,580
23,342
0
0
0
0
0
0
0
14
14
14
0
0
00141414000000023,34215,58018,71120,53724,29102,6022,8573,0993,32712134,0062003494656007348,3582,04761146943388000000
       Deferred Long Term Liability 
0
0
0
0
19,135
0
3,846
3,096
2,896
2,802
2,796
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000002,7962,8022,8963,0963,846019,1350000
> Total Stockholder Equity
94,608
94,608
0
0
88,618
118,846
97,197
63,750
50,566
61,486
51,420
90,310
82,035
68,364
56,030
44,000
30,406
39,130
26,199
19,745
11,842
15,152
8,650
2,202
16,594
10,504
13,881
7,292
1,216
-5,884
23,047
15,762
17,974
23,256
16,253
14,718
12,221
6,103
4,463
4,420
4,755
-1,473
-1,4734,7554,4204,4636,10312,22114,71816,25323,25617,97415,76223,047-5,8841,2167,29213,88110,50416,5942,2028,65015,15211,84219,74526,19939,13030,40644,00056,03068,36482,03590,31051,42061,48650,56663,75097,197118,84688,6180094,60894,608
   Common Stock
267,279
0
0
0
320,606
20
354,913
20
20
21
21
21
22
22
23
23
23
45
45
45
45
45
45
45
46
46
47
47
47
47
47
47
48
49
49
56
61
66
69
82
84
84
8484826966615649494847474747474746464545454545454523232322222121212020354,91320320,606000267,279
   Retained Earnings -253,985-247,577-241,265-236,164-230,281-223,447-217,545-211,211-203,263-206,036-201,394-193,750-221,760-214,063-207,791-200,794-192,862-185,606-178,553-171,762-164,959-167,856-159,682-152,758-139,426-127,408-113,279-100,717-87,573-73,719-63,958-101,826-90,637-80,692-65,746-257,716-244,878-231,988000-172,671
   Capital Surplus 
0
0
0
0
0
0
0
149,493
151,271
152,143
153,239
154,257
155,837
155,998
156,760
157,258
157,791
178,511
178,912
179,382
179,653
180,066
180,367
180,710
0
203,320
214,628
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000214,628203,3200180,710180,367180,066179,653179,382178,912178,511157,791157,258156,760155,998155,837154,257153,239152,143151,271149,4930000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
320,606
363,704
354,913
129,493
131,271
152,143
153,239
154,257
155,837
155,998
156,760
157,258
157,791
178,511
178,912
179,382
179,653
180,066
180,367
180,710
202,154
203,320
214,628
215,036
215,232
215,829
216,750
217,109
223,962
226,470
227,415
232,207
235,607
236,318
240,558
245,603
252,248
252,428
252,428252,248245,603240,558236,318235,607232,207227,415226,470223,962217,109216,750215,829215,232215,036214,628203,320202,154180,710180,367180,066179,653179,382178,912178,511157,791157,258156,760155,998155,837154,257153,239152,143131,271129,493354,913363,704320,6060000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-352
Gross Profit0-352
 
Operating Income (+$)
Gross Profit0
Operating Expense-24,602
Operating Income-24,602-24,602
 
Operating Expense (+$)
Research Development14,026
Selling General Administrative10,224
Selling And Marketing Expenses0
Operating Expense24,60224,250
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-24,602
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,130-25,074
EBIT - interestExpense = -24,130
-24,130
-24,130
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-24,130-24,130
Earnings Before Interest and Taxes (EBITDA)-23,778
 
After tax Income (+$)
Income Before Tax-24,130
Tax Provision-0
Net Income From Continuing Ops-24,130-24,130
Net Income-24,130
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net4720
 

Technical Analysis of Aptevo Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aptevo Therapeutics Inc. The general trend of Aptevo Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aptevo Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aptevo Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aptevo Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 13.11 < 14.33 < 18.85.

The bearish price targets are: 2.81.

Know someone who trades $APVO? Share this with them.πŸ‘‡

Aptevo Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aptevo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aptevo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aptevo Therapeutics Inc. The current macd is -1.23717279.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aptevo Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aptevo Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aptevo Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aptevo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAptevo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aptevo Therapeutics Inc. The current adx is 28.04.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aptevo Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Aptevo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aptevo Therapeutics Inc. The current sar is 8.98100678.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aptevo Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aptevo Therapeutics Inc. The current rsi is 33.93. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Aptevo Therapeutics Inc Daily Relative Strength Index (RSI) ChartAptevo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aptevo Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aptevo Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Aptevo Therapeutics Inc Daily Stochastic Oscillator ChartAptevo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aptevo Therapeutics Inc. The current cci is -78.4842936.

Aptevo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAptevo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aptevo Therapeutics Inc. The current cmo is -27.20304703.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aptevo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAptevo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aptevo Therapeutics Inc. The current willr is -97.76696861.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Aptevo Therapeutics Inc Daily Williams %R ChartAptevo Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aptevo Therapeutics Inc. The current atr is 1.06579292.

Aptevo Therapeutics Inc Daily Average True Range (ATR) ChartAptevo Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aptevo Therapeutics Inc. The current obv is 126,627,899.

Aptevo Therapeutics Inc Daily On-Balance Volume (OBV) ChartAptevo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aptevo Therapeutics Inc. The current mfi is 97.33.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Aptevo Therapeutics Inc Daily Money Flow Index (MFI) ChartAptevo Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aptevo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-25MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Aptevo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aptevo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.934
Ma 20Greater thanMa 503.851
Ma 50Greater thanMa 1006.209
Ma 100Greater thanMa 20025.905
OpenGreater thanClose3.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aptevo Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Aptevo Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aptevo Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aptevo Therapeutics Inc

I send you an email if I find something interesting about Aptevo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aptevo Therapeutics Inc.

Receive notifications about Aptevo Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.